Centessa Pharmaceuticals (CNTA) News Today $17.16 -0.39 (-2.22%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 55,000 SharesDecember 21 at 7:24 AM | insidertrades.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $959,200.00 in StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $17.44, for a total transaction of $959,200.00. Following the transaction, the chief executive officer now directly owns 520,661 shares of the company's stock, valued at $9,080,327.84. The trade was a 9.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.December 20 at 7:29 PM | marketbeat.comWhy Did Centessa Pharmaceuticals PLC (CNTA) Jump Yesterday?December 20 at 11:55 AM | msn.comWellington Management Group LLP Purchases New Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Wellington Management Group LLP bought a new stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 100,613 shares of the company's stock, valued at approximately $1,609December 19 at 3:33 AM | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Karen M. Anderson Sells 5,876 SharesDecember 18 at 6:22 AM | insidertrades.comFranklin Resources Inc. Grows Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Franklin Resources Inc. grew its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 99.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,302,546 shares of the company's stock after buying an additional 1December 18 at 4:55 AM | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 5,876 SharesCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Karen M. Anderson sold 5,876 shares of the company's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $17.01, for a total transaction of $99,950.76. Following the completion of the transaction, the insider now owns 71,525 shares of the company's stock, valued at approximately $1,216,640.25. The trade was a 7.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.December 17, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Karen M. Anderson Sells 10,624 SharesCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Karen M. Anderson sold 10,624 shares of the firm's stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $17.32, for a total value of $184,007.68. Following the sale, the insider now directly owns 71,525 shares in the company, valued at approximately $1,238,813. This represents a 12.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.December 17, 2024 | marketbeat.comTia L. Bush Sells 17,813 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CTO Tia L. Bush sold 17,813 shares of the firm's stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $18.00, for a total transaction of $320,634.00. Following the sale, the chief technology officer now owns 147,615 shares of the company's stock, valued at approximately $2,657,070. This represents a 10.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.December 17, 2024 | marketbeat.comIqbal J. Hussain Sells 77,705 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) General Counsel Iqbal J. Hussain sold 77,705 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $16.39, for a total transaction of $1,273,584.95. Following the sale, the general counsel now owns 125,785 shares of the company's stock, valued at approximately $2,061,616.15. The trade was a 38.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.December 17, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Trading Up 4.3% - Time to Buy?Centessa Pharmaceuticals (NASDAQ:CNTA) Trading 4.3% Higher - Still a Buy?December 17, 2024 | marketbeat.comLord Abbett & CO. LLC Makes New Investment in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Lord Abbett & CO. LLC bought a new stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 269,205 shares of the company's stock, valued at approxiDecember 17, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest Up 37.3% in NovemberCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 3,350,000 shares, an increase of 37.3% from the November 15th total of 2,440,000 shares. Based on an average trading volume of 680,400 shares, the days-to-cover ratio is presently 4.9 days. Currently, 3.8% of the company's stock are short sold.December 13, 2024 | marketbeat.com1,294,864 Shares in Centessa Pharmaceuticals plc (NASDAQ:CNTA) Bought by Janus Henderson Group PLCJanus Henderson Group PLC purchased a new stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,294,864 shareDecember 8, 2024 | marketbeat.comFmr LLC Boosts Stock Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Fmr LLC grew its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 4.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,916,494 shares of the company's stock after buying an additional 129,300 shareDecember 8, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $1,615,176.16 in StockDecember 7, 2024 | insidertrades.comCentessa Pharmaceuticals (NASDAQ:CNTA) Hits New 52-Week High - Still a Buy?Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 1-Year High - Should You Buy?December 7, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Has $4.24 Million Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)The Manufacturers Life Insurance Company boosted its position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 88.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 26December 7, 2024 | marketbeat.comSaurabh Saha Sells 87,496 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 87,496 shares of the company's stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $18.46, for a total value of $1,615,176.16. Following the transaction, the chief executive officer now directly owns 575,661 shares of the company's stock, valued at $10,626,702.06. The trade was a 13.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.December 6, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Trading 5.9% Higher - Should You Buy?Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Up 5.9% - Here's What HappenedDecember 6, 2024 | marketbeat.comCentessa management to meet with OppenheimerDecember 5, 2024 | markets.businessinsider.comRTW Investments LP Makes New Investment in Centessa Pharmaceuticals plc (NASDAQ:CNTA)RTW Investments LP acquired a new position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 50,000 shares of the company's stock, valDecember 5, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Purchased by Point72 Asset Management L.P.Point72 Asset Management L.P. increased its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 54.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,715,663 shares of the company's sDecember 5, 2024 | marketbeat.comHighVista Strategies LLC Takes $737,000 Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)HighVista Strategies LLC bought a new stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 46,116 shares of the compDecember 3, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Given Average Recommendation of "Buy" by BrokeragesCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) has received an average rating of "Buy" from the six research firms that are presently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12-month target price among bDecember 3, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Bought by Baker BROS. Advisors LPBaker BROS. Advisors LP increased its stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 123.4% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,227,178 shares of the company's stock after acquiring an adDecember 2, 2024 | marketbeat.comFred Alger Management LLC Boosts Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Fred Alger Management LLC grew its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 1,515.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 177,553 shares of the company's stock after purchasingDecember 2, 2024 | marketbeat.comSuvretta Capital Management LLC Invests $1.12 Million in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Suvretta Capital Management LLC bought a new position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 70,000 shares of the company's stock, valued aNovember 29, 2024 | marketbeat.comAlly Bridge Group NY LLC Takes Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Ally Bridge Group NY LLC bought a new position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm bought 309,614 shares of the company's stock, valued at approximately $4,951,000. Centessa PharmaceuticalsNovember 28, 2024 | marketbeat.comGregory M. Weinhoff Sells 10,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockNovember 28, 2024 | insidertrades.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells 1,671 Shares of StockNovember 23, 2024 | insidertrades.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 1,671 SharesCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $18.24, for a total value of $30,479.04. Following the completion of the sale, the chief executive officer now directly owns 575,661 shares of the company's stock, valued at $10,500,056.64. The trade was a 0.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.November 22, 2024 | marketbeat.comSaurabh Saha Sells 55,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 55,000 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.89, for a total value of $928,950.00. Following the sale, the chief executive officer now directly owns 575,661 shares of the company's stock, valued at approximately $9,722,914.29. This represents a 8.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.November 22, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 4.5% - Should You Sell?Centessa Pharmaceuticals (NASDAQ:CNTA) Trading Down 4.5% - Here's What HappenedNovember 22, 2024 | marketbeat.comFY2024 Earnings Estimate for CNTA Issued By Leerink PartnrsCentessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - Equities researchers at Leerink Partnrs upped their FY2024 earnings estimates for shares of Centessa Pharmaceuticals in a research note issued on Wednesday, November 20th. Leerink Partnrs analyst D. Risinger now expects that the company wNovember 22, 2024 | marketbeat.comShort Interest in Centessa Pharmaceuticals plc (NASDAQ:CNTA) Increases By 7.0%Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 2,150,000 shares, a growth of 7.0% from the October 15th total of 2,010,000 shares. Currently, 2.7% of the shares of the company are short sold. Based on an average daily trading volume, of 604,100 shares, the days-to-cover ratio is presently 3.6 days.November 17, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Price Target Raised to $28.00 at GuggenheimGuggenheim raised their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a report on Friday.November 15, 2024 | marketbeat.comB. Riley Has Positive Outlook for CNTA FY2024 EarningsCentessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - Research analysts at B. Riley increased their FY2024 earnings per share estimates for Centessa Pharmaceuticals in a research report issued on Tuesday, November 12th. B. Riley analyst M. Mamtani now expects that the company will post earniNovember 15, 2024 | marketbeat.comBuy Rating for Centessa Pharmaceuticals: Promising Orexin Program and Strategic Portfolio AdvancesNovember 14, 2024 | markets.businessinsider.comCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Down - Here's What HappenedCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Down - Time to Sell?November 14, 2024 | marketbeat.comCentessa Pharmaceuticals’ ORX750: Promising Efficacy and Strategic Positioning Reinforce Buy RatingNovember 14, 2024 | markets.businessinsider.comGSA Capital Partners LLP Increases Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)GSA Capital Partners LLP lifted its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 66.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 93,658 shares of the company's stock after acquiring an additionaNovember 14, 2024 | marketbeat.comGSA Capital Partners LLP Has $1.50 Million Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)GSA Capital Partners LLP grew its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 66.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 93,658 shares of the company's stock after buying anNovember 14, 2024 | marketbeat.comCentessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business UpdateNovember 13, 2024 | finanznachrichten.deNxera Pharma's Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) AgonistNovember 13, 2024 | finanznachrichten.deCentessa Pharmaceuticals Advances Pipeline with Promising OX2R DataNovember 13, 2024 | markets.businessinsider.comCentessa Pharmaceuticals (NASDAQ:CNTA) Sets New 1-Year High - What's Next?Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 1-Year High - Should You Buy?November 12, 2024 | marketbeat.comCentessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business UpdateNovember 12, 2024 | globenewswire.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Given Average Rating of "Buy" by AnalystsShares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) have earned an average rating of "Buy" from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month pNovember 8, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Quotes, Forecast and News SummaryNovember 1, 2024 | benzinga.com Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address How Low-Cost Stocks Generate Monthly Income (Ad)Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE! 👉 Yes, I Want the Free Report! 👈 CNTA Media Mentions By Week CNTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTA News Sentiment▼0.540.61▲Average Medical News Sentiment CNTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTA Articles This Week▼174▲CNTA Articles Average Week Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ASND News RVMD News LNTH News NUVL News BPMC News ELAN News LEGN News CYTK News TGTX News VKTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNTA Stock Alerts